1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Lipid-lowering Drugs Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Lipid-lowering Drugs by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Lipid-lowering Drugs by Country/Region, 2018, 2022 & 2029
2.2 Lipid-lowering Drugs Segment by Type
2.2.1 Statins & Combination
2.2.2 PCSK9 Inhibitors
2.2.3 Bile Acid Sequestrants
2.2.4 Fibrates
2.2.5 Cholesterol Absorption Inhibitors
2.2.6 Others
2.3 Lipid-lowering Drugs Sales by Type
2.3.1 Global Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
2.3.2 Global Lipid-lowering Drugs Revenue and Market Share by Type (2018-2023)
2.3.3 Global Lipid-lowering Drugs Sale Price by Type (2018-2023)
2.4 Lipid-lowering Drugs Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Lipid-lowering Drugs Sales by Application
2.5.1 Global Lipid-lowering Drugs Sale Market Share by Application (2018-2023)
2.5.2 Global Lipid-lowering Drugs Revenue and Market Share by Application (2018-2023)
2.5.3 Global Lipid-lowering Drugs Sale Price by Application (2018-2023)
3 Global Lipid-lowering Drugs by Company
3.1 Global Lipid-lowering Drugs Breakdown Data by Company
3.1.1 Global Lipid-lowering Drugs Annual Sales by Company (2018-2023)
3.1.2 Global Lipid-lowering Drugs Sales Market Share by Company (2018-2023)
3.2 Global Lipid-lowering Drugs Annual Revenue by Company (2018-2023)
3.2.1 Global Lipid-lowering Drugs Revenue by Company (2018-2023)
3.2.2 Global Lipid-lowering Drugs Revenue Market Share by Company (2018-2023)
3.3 Global Lipid-lowering Drugs Sale Price by Company
3.4 Key Manufacturers Lipid-lowering Drugs Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Lipid-lowering Drugs Product Location Distribution
3.4.2 Players Lipid-lowering Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Lipid-lowering Drugs by Geographic Region
4.1 World Historic Lipid-lowering Drugs Market Size by Geographic Region (2018-2023)
4.1.1 Global Lipid-lowering Drugs Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Lipid-lowering Drugs Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Lipid-lowering Drugs Market Size by Country/Region (2018-2023)
4.2.1 Global Lipid-lowering Drugs Annual Sales by Country/Region (2018-2023)
4.2.2 Global Lipid-lowering Drugs Annual Revenue by Country/Region (2018-2023)
4.3 Americas Lipid-lowering Drugs Sales Growth
4.4 APAC Lipid-lowering Drugs Sales Growth
4.5 Europe Lipid-lowering Drugs Sales Growth
4.6 Middle East & Africa Lipid-lowering Drugs Sales Growth
5 Americas
5.1 Americas Lipid-lowering Drugs Sales by Country
5.1.1 Americas Lipid-lowering Drugs Sales by Country (2018-2023)
5.1.2 Americas Lipid-lowering Drugs Revenue by Country (2018-2023)
5.2 Americas Lipid-lowering Drugs Sales by Type
5.3 Americas Lipid-lowering Drugs Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Lipid-lowering Drugs Sales by Region
6.1.1 APAC Lipid-lowering Drugs Sales by Region (2018-2023)
6.1.2 APAC Lipid-lowering Drugs Revenue by Region (2018-2023)
6.2 APAC Lipid-lowering Drugs Sales by Type
6.3 APAC Lipid-lowering Drugs Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Lipid-lowering Drugs by Country
7.1.1 Europe Lipid-lowering Drugs Sales by Country (2018-2023)
7.1.2 Europe Lipid-lowering Drugs Revenue by Country (2018-2023)
7.2 Europe Lipid-lowering Drugs Sales by Type
7.3 Europe Lipid-lowering Drugs Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Lipid-lowering Drugs by Country
8.1.1 Middle East & Africa Lipid-lowering Drugs Sales by Country (2018-2023)
8.1.2 Middle East & Africa Lipid-lowering Drugs Revenue by Country (2018-2023)
8.2 Middle East & Africa Lipid-lowering Drugs Sales by Type
8.3 Middle East & Africa Lipid-lowering Drugs Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Lipid-lowering Drugs
10.3 Manufacturing Process Analysis of Lipid-lowering Drugs
10.4 Industry Chain Structure of Lipid-lowering Drugs
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Lipid-lowering Drugs Distributors
11.3 Lipid-lowering Drugs Customer
12 World Forecast Review for Lipid-lowering Drugs by Geographic Region
12.1 Global Lipid-lowering Drugs Market Size Forecast by Region
12.1.1 Global Lipid-lowering Drugs Forecast by Region (2024-2029)
12.1.2 Global Lipid-lowering Drugs Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Lipid-lowering Drugs Forecast by Type
12.7 Global Lipid-lowering Drugs Forecast by Application
13 Key Players Analysis
13.1 Sanofi
13.1.1 Sanofi Company Information
13.1.2 Sanofi Lipid-lowering Drugs Product Portfolios and Specifications
13.1.3 Sanofi Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Sanofi Main Business Overview
13.1.5 Sanofi Latest Developments
13.2 Pfizer, Inc.
13.2.1 Pfizer, Inc. Company Information
13.2.2 Pfizer, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.2.3 Pfizer, Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Pfizer, Inc. Main Business Overview
13.2.5 Pfizer, Inc. Latest Developments
13.3 GlaxoSmithKline plc
13.3.1 GlaxoSmithKline plc Company Information
13.3.2 GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolios and Specifications
13.3.3 GlaxoSmithKline plc Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 GlaxoSmithKline plc Main Business Overview
13.3.5 GlaxoSmithKline plc Latest Developments
13.4 Novartis AG
13.4.1 Novartis AG Company Information
13.4.2 Novartis AG Lipid-lowering Drugs Product Portfolios and Specifications
13.4.3 Novartis AG Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis AG Main Business Overview
13.4.5 Novartis AG Latest Developments
13.5 Merck & Co., Inc.
13.5.1 Merck & Co., Inc. Company Information
13.5.2 Merck & Co., Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.5.3 Merck & Co., Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Merck & Co., Inc. Main Business Overview
13.5.5 Merck & Co., Inc. Latest Developments
13.6 Amgen Inc.
13.6.1 Amgen Inc. Company Information
13.6.2 Amgen Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.6.3 Amgen Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Amgen Inc. Main Business Overview
13.6.5 Amgen Inc. Latest Developments
13.7 Takeda Pharmaceutical Company Limited
13.7.1 Takeda Pharmaceutical Company Limited Company Information
13.7.2 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolios and Specifications
13.7.3 Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Takeda Pharmaceutical Company Limited Main Business Overview
13.7.5 Takeda Pharmaceutical Company Limited Latest Developments
13.8 Sun Pharmaceutical Industries Ltd.
13.8.1 Sun Pharmaceutical Industries Ltd. Company Information
13.8.2 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
13.8.3 Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
13.8.5 Sun Pharmaceutical Industries Ltd. Latest Developments
13.9 AbbVie, Inc.
13.9.1 AbbVie, Inc. Company Information
13.9.2 AbbVie, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
13.9.3 AbbVie, Inc. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 AbbVie, Inc. Main Business Overview
13.9.5 AbbVie, Inc. Latest Developments
13.10 Viatris (Mylan N.V.)
13.10.1 Viatris (Mylan N.V.) Company Information
13.10.2 Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolios and Specifications
13.10.3 Viatris (Mylan N.V.) Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Viatris (Mylan N.V.) Main Business Overview
13.10.5 Viatris (Mylan N.V.) Latest Developments
13.11 AstraZeneca PLC
13.11.1 AstraZeneca PLC Company Information
13.11.2 AstraZeneca PLC Lipid-lowering Drugs Product Portfolios and Specifications
13.11.3 AstraZeneca PLC Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca PLC Main Business Overview
13.11.5 AstraZeneca PLC Latest Developments
13.12 Dr. Reddy’s Laboratories Ltd.
13.12.1 Dr. Reddy’s Laboratories Ltd. Company Information
13.12.2 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
13.12.3 Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Dr. Reddy’s Laboratories Ltd. Main Business Overview
13.12.5 Dr. Reddy’s Laboratories Ltd. Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Lipid-lowering Drugs Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Lipid-lowering Drugs Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Statins & Combination
Table 4. Major Players of PCSK9 Inhibitors
Table 5. Major Players of Bile Acid Sequestrants
Table 6. Major Players of Fibrates
Table 7. Major Players of Cholesterol Absorption Inhibitors
Table 8. Major Players of Others
Table 9. Global Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 10. Global Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Table 11. Global Lipid-lowering Drugs Revenue by Type (2018-2023) & ($ million)
Table 12. Global Lipid-lowering Drugs Revenue Market Share by Type (2018-2023)
Table 13. Global Lipid-lowering Drugs Sale Price by Type (2018-2023) & (US$/Unit)
Table 14. Global Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 15. Global Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Table 16. Global Lipid-lowering Drugs Revenue by Application (2018-2023)
Table 17. Global Lipid-lowering Drugs Revenue Market Share by Application (2018-2023)
Table 18. Global Lipid-lowering Drugs Sale Price by Application (2018-2023) & (US$/Unit)
Table 19. Global Lipid-lowering Drugs Sales by Company (2018-2023) & (K Units)
Table 20. Global Lipid-lowering Drugs Sales Market Share by Company (2018-2023)
Table 21. Global Lipid-lowering Drugs Revenue by Company (2018-2023) ($ Millions)
Table 22. Global Lipid-lowering Drugs Revenue Market Share by Company (2018-2023)
Table 23. Global Lipid-lowering Drugs Sale Price by Company (2018-2023) & (US$/Unit)
Table 24. Key Manufacturers Lipid-lowering Drugs Producing Area Distribution and Sales Area
Table 25. Players Lipid-lowering Drugs Products Offered
Table 26. Lipid-lowering Drugs Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 27. New Products and Potential Entrants
Table 28. Mergers & Acquisitions, Expansion
Table 29. Global Lipid-lowering Drugs Sales by Geographic Region (2018-2023) & (K Units)
Table 30. Global Lipid-lowering Drugs Sales Market Share Geographic Region (2018-2023)
Table 31. Global Lipid-lowering Drugs Revenue by Geographic Region (2018-2023) & ($ millions)
Table 32. Global Lipid-lowering Drugs Revenue Market Share by Geographic Region (2018-2023)
Table 33. Global Lipid-lowering Drugs Sales by Country/Region (2018-2023) & (K Units)
Table 34. Global Lipid-lowering Drugs Sales Market Share by Country/Region (2018-2023)
Table 35. Global Lipid-lowering Drugs Revenue by Country/Region (2018-2023) & ($ millions)
Table 36. Global Lipid-lowering Drugs Revenue Market Share by Country/Region (2018-2023)
Table 37. Americas Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 38. Americas Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 39. Americas Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 40. Americas Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 41. Americas Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 42. Americas Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 43. APAC Lipid-lowering Drugs Sales by Region (2018-2023) & (K Units)
Table 44. APAC Lipid-lowering Drugs Sales Market Share by Region (2018-2023)
Table 45. APAC Lipid-lowering Drugs Revenue by Region (2018-2023) & ($ Millions)
Table 46. APAC Lipid-lowering Drugs Revenue Market Share by Region (2018-2023)
Table 47. APAC Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 48. APAC Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 49. Europe Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 50. Europe Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 51. Europe Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 52. Europe Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 53. Europe Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 54. Europe Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 55. Middle East & Africa Lipid-lowering Drugs Sales by Country (2018-2023) & (K Units)
Table 56. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Country (2018-2023)
Table 57. Middle East & Africa Lipid-lowering Drugs Revenue by Country (2018-2023) & ($ Millions)
Table 58. Middle East & Africa Lipid-lowering Drugs Revenue Market Share by Country (2018-2023)
Table 59. Middle East & Africa Lipid-lowering Drugs Sales by Type (2018-2023) & (K Units)
Table 60. Middle East & Africa Lipid-lowering Drugs Sales by Application (2018-2023) & (K Units)
Table 61. Key Market Drivers & Growth Opportunities of Lipid-lowering Drugs
Table 62. Key Market Challenges & Risks of Lipid-lowering Drugs
Table 63. Key Industry Trends of Lipid-lowering Drugs
Table 64. Lipid-lowering Drugs Raw Material
Table 65. Key Suppliers of Raw Materials
Table 66. Lipid-lowering Drugs Distributors List
Table 67. Lipid-lowering Drugs Customer List
Table 68. Global Lipid-lowering Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 69. Global Lipid-lowering Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Americas Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 71. Americas Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. APAC Lipid-lowering Drugs Sales Forecast by Region (2024-2029) & (K Units)
Table 73. APAC Lipid-lowering Drugs Revenue Forecast by Region (2024-2029) & ($ millions)
Table 74. Europe Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 75. Europe Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 76. Middle East & Africa Lipid-lowering Drugs Sales Forecast by Country (2024-2029) & (K Units)
Table 77. Middle East & Africa Lipid-lowering Drugs Revenue Forecast by Country (2024-2029) & ($ millions)
Table 78. Global Lipid-lowering Drugs Sales Forecast by Type (2024-2029) & (K Units)
Table 79. Global Lipid-lowering Drugs Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 80. Global Lipid-lowering Drugs Sales Forecast by Application (2024-2029) & (K Units)
Table 81. Global Lipid-lowering Drugs Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 82. Sanofi Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 83. Sanofi Lipid-lowering Drugs Product Portfolios and Specifications
Table 84. Sanofi Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 85. Sanofi Main Business
Table 86. Sanofi Latest Developments
Table 87. Pfizer, Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 88. Pfizer, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 89. Pfizer, Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 90. Pfizer, Inc. Main Business
Table 91. Pfizer, Inc. Latest Developments
Table 92. GlaxoSmithKline plc Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 93. GlaxoSmithKline plc Lipid-lowering Drugs Product Portfolios and Specifications
Table 94. GlaxoSmithKline plc Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 95. GlaxoSmithKline plc Main Business
Table 96. GlaxoSmithKline plc Latest Developments
Table 97. Novartis AG Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 98. Novartis AG Lipid-lowering Drugs Product Portfolios and Specifications
Table 99. Novartis AG Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 100. Novartis AG Main Business
Table 101. Novartis AG Latest Developments
Table 102. Merck & Co., Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 103. Merck & Co., Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 104. Merck & Co., Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 105. Merck & Co., Inc. Main Business
Table 106. Merck & Co., Inc. Latest Developments
Table 107. Amgen Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 108. Amgen Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 109. Amgen Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 110. Amgen Inc. Main Business
Table 111. Amgen Inc. Latest Developments
Table 112. Takeda Pharmaceutical Company Limited Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 113. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Product Portfolios and Specifications
Table 114. Takeda Pharmaceutical Company Limited Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 115. Takeda Pharmaceutical Company Limited Main Business
Table 116. Takeda Pharmaceutical Company Limited Latest Developments
Table 117. Sun Pharmaceutical Industries Ltd. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 118. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
Table 119. Sun Pharmaceutical Industries Ltd. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 120. Sun Pharmaceutical Industries Ltd. Main Business
Table 121. Sun Pharmaceutical Industries Ltd. Latest Developments
Table 122. AbbVie, Inc. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 123. AbbVie, Inc. Lipid-lowering Drugs Product Portfolios and Specifications
Table 124. AbbVie, Inc. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 125. AbbVie, Inc. Main Business
Table 126. AbbVie, Inc. Latest Developments
Table 127. Viatris (Mylan N.V.) Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 128. Viatris (Mylan N.V.) Lipid-lowering Drugs Product Portfolios and Specifications
Table 129. Viatris (Mylan N.V.) Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 130. Viatris (Mylan N.V.) Main Business
Table 131. Viatris (Mylan N.V.) Latest Developments
Table 132. AstraZeneca PLC Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 133. AstraZeneca PLC Lipid-lowering Drugs Product Portfolios and Specifications
Table 134. AstraZeneca PLC Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 135. AstraZeneca PLC Main Business
Table 136. AstraZeneca PLC Latest Developments
Table 137. Dr. Reddy’s Laboratories Ltd. Basic Information, Lipid-lowering Drugs Manufacturing Base, Sales Area and Its Competitors
Table 138. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Product Portfolios and Specifications
Table 139. Dr. Reddy’s Laboratories Ltd. Lipid-lowering Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 140. Dr. Reddy’s Laboratories Ltd. Main Business
Table 141. Dr. Reddy’s Laboratories Ltd. Latest Developments
List of Figures
Figure 1. Picture of Lipid-lowering Drugs
Figure 2. Lipid-lowering Drugs Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Lipid-lowering Drugs Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Lipid-lowering Drugs Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Lipid-lowering Drugs Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Statins & Combination
Figure 10. Product Picture of PCSK9 Inhibitors
Figure 11. Product Picture of Bile Acid Sequestrants
Figure 12. Product Picture of Fibrates
Figure 13. Product Picture of Cholesterol Absorption Inhibitors
Figure 14. Product Picture of Others
Figure 15. Global Lipid-lowering Drugs Sales Market Share by Type in 2022
Figure 16. Global Lipid-lowering Drugs Revenue Market Share by Type (2018-2023)
Figure 17. Lipid-lowering Drugs Consumed in Hospital Pharmacies
Figure 18. Global Lipid-lowering Drugs Market: Hospital Pharmacies (2018-2023) & (K Units)
Figure 19. Lipid-lowering Drugs Consumed in Retail Pharmacies
Figure 20. Global Lipid-lowering Drugs Market: Retail Pharmacies (2018-2023) & (K Units)
Figure 21. Lipid-lowering Drugs Consumed in Online Pharmacies
Figure 22. Global Lipid-lowering Drugs Market: Online Pharmacies (2018-2023) & (K Units)
Figure 23. Global Lipid-lowering Drugs Sales Market Share by Application (2022)
Figure 24. Global Lipid-lowering Drugs Revenue Market Share by Application in 2022
Figure 25. Lipid-lowering Drugs Sales Market by Company in 2022 (K Units)
Figure 26. Global Lipid-lowering Drugs Sales Market Share by Company in 2022
Figure 27. Lipid-lowering Drugs Revenue Market by Company in 2022 ($ Million)
Figure 28. Global Lipid-lowering Drugs Revenue Market Share by Company in 2022
Figure 29. Global Lipid-lowering Drugs Sales Market Share by Geographic Region (2018-2023)
Figure 30. Global Lipid-lowering Drugs Revenue Market Share by Geographic Region in 2022
Figure 31. Americas Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 32. Americas Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 33. APAC Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 34. APAC Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 35. Europe Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 36. Europe Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 37. Middle East & Africa Lipid-lowering Drugs Sales 2018-2023 (K Units)
Figure 38. Middle East & Africa Lipid-lowering Drugs Revenue 2018-2023 ($ Millions)
Figure 39. Americas Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 40. Americas Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 41. Americas Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 42. Americas Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 43. United States Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 44. Canada Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 45. Mexico Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 46. Brazil Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 47. APAC Lipid-lowering Drugs Sales Market Share by Region in 2022
Figure 48. APAC Lipid-lowering Drugs Revenue Market Share by Regions in 2022
Figure 49. APAC Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 50. APAC Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 51. China Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 52. Japan Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 53. South Korea Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 54. Southeast Asia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 55. India Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 56. Australia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 57. China Taiwan Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 58. Europe Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 59. Europe Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 60. Europe Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 61. Europe Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 62. Germany Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 63. France Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 64. UK Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 65. Italy Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 66. Russia Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 67. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Country in 2022
Figure 68. Middle East & Africa Lipid-lowering Drugs Revenue Market Share by Country in 2022
Figure 69. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Type (2018-2023)
Figure 70. Middle East & Africa Lipid-lowering Drugs Sales Market Share by Application (2018-2023)
Figure 71. Egypt Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 72. South Africa Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 73. Israel Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 74. Turkey Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 75. GCC Country Lipid-lowering Drugs Revenue Growth 2018-2023 ($ Millions)
Figure 76. Manufacturing Cost Structure Analysis of Lipid-lowering Drugs in 2022
Figure 77. Manufacturing Process Analysis of Lipid-lowering Drugs
Figure 78. Industry Chain Structure of Lipid-lowering Drugs
Figure 79. Channels of Distribution
Figure 80. Global Lipid-lowering Drugs Sales Market Forecast by Region (2024-2029)
Figure 81. Global Lipid-lowering Drugs Revenue Market Share Forecast by Region (2024-2029)
Figure 82. Global Lipid-lowering Drugs Sales Market Share Forecast by Type (2024-2029)
Figure 83. Global Lipid-lowering Drugs Revenue Market Share Forecast by Type (2024-2029)
Figure 84. Global Lipid-lowering Drugs Sales Market Share Forecast by Application (2024-2029)
Figure 85. Global Lipid-lowering Drugs Revenue Market Share Forecast by Application (2024-2029)

※参考情報 脂質低下薬剤は、高脂血症や動脈硬化症の予防と治療に用いられる薬剤の総称です。これらの薬剤は、血中の脂質、主にコレステロールや中性脂肪のレベルを低下させることを目的としています。脂質異常症は、心血管疾患のリスクファクターとして広く認識されており、そのため脂質低下薬は多くの患者にとって重要な治療手段となっています。 脂質低下薬剤の定義は、血液中の脂質濃度を調整し、動脈の健康を守るために設計された薬剤を指します。これらの薬剤は、リピッドプロファイルを改善し、心臓病や脳卒中などの重篤な疾患のリスクを低下させることが期待されます。脂質はセルメンブレンの構成成分であるため、過剰なコレステロールや中性脂肪は、動脈内に沈着し、プラークの形成を引き起こすことがあります。これが進行すると、血流が阻害され、心血管系の病気が発生することがあるため、脂質低下薬の使用は非常に重要です。 脂質低下薬の特徴としては、いくつかの重要なポイントが挙げられます。まず、脂質低下薬はその作用メカニズムに基づいて分類されます。これにより、異なるタイプの薬剤が異なる方法で血中脂質を調整します。また、これらの薬剤は通常、長期的な使用が必要であり、服用を続けることで効果を発揮します。さらに、生活習慣の改善と併用することが推奨されており、食事や運動、禁煙などの生活習慣の見直しが治療効果を高めることが知られています。 脂質低下薬には、いくつかの主要な種類があります。一つ目はスタチン系薬剤です。スタチンは、肝臓でのコレステロール合成を抑制することにより、血中のLDL（低密度リポタンパク質）コレステロールを減少させる働きがあります。具体的な薬剤としては、アトルバスタチン、シンバスタチン、ロスバスタチンなどがあり、これらは心血管疾患の予防において高い効果を示すことが多くの研究で確認されています。 次に、フィブラート系薬剤があります。これらは主に中性脂肪を低下させ、HDL（高密度リポタンパク質）コレステロールを上昇させることが特徴です。代表的なフィブラートには、フェノフィブラートやジオフブリジオルが含まれます。特にトリグリセリド（中性脂肪）が高い患者に対して処方されることが多いです。 また、胆汁酸吸着薬もです。これらは腸内で胆汁酸を吸着し、コレステロールの排出を促進することで効果を発揮します。コレステロールを包み込んで体外に排出させるため、これらの薬剤は他の薬剤と併用することが一般的です。代表的な薬剤には、コレスチラミンやコレスチミドなどがあります。 近年注目されているのは、PCSK9阻害薬です。これは、低密度リポタンパク質受容体の分解を抑制することによって、LDLコレステロールのレベルを大幅に低下させることができます。主に重度の高LDLコレステロール血症の患者や、スタチンによる十分な効果が得られない患者に対して使用されます。アリクズマブやエボロクマブがこのカテゴリの薬剤です。 最後に、オメガ-3脂肪酸製剤も脂質低下薬の一種として位置づけられています。これらは主に中性脂肪を減少させる働きがあり、心血管リスクを低下させることが示されています。これらは常に適切な食事とともに摂取されることが望ましいです。 脂質低下薬の用途は、主に心血管疾患の予防と治療、ならびに脂質異常症の治療に限られます。特に心筋梗塞や脳卒中の予防として、LDLコレステロールのレベルをコントロールするために用いられます。また、これらの薬剤は、糖尿病や高血圧を持つ患者に対しても使用されることがあり、これらの疾患は心血管リスクを増加させるため、トータルでの健康管理が求められます。 さらに、関連技術としては、個別化医療の進展が挙げられます。遺伝的要因や生活習慣に基づいた患者ごとのリスク評価が行われ、最も適した脂質低下薬の選択につながります。最近では、遺伝子解析を用いた個别化治療の研究が進められており、将来的には特定の患者に対して最適な薬剤を提案することが可能になると考えられています。これにより、より効果的な治療が実現し、副作用を軽減することが期待されています。 脂質低下薬は、心血管疾患の予防および治療において重要な役割を果たしており、適切な使用と生活習慣の改善との組み合わせによって、患者の健康管理に大いに寄与しています。今後も新たな治療法や薬剤の開発が期待される中、最新の知見に基づく治療が求められています。患者一人ひとりに最適な脂質管理を行い、健康的な生活をサポートするために、医療従事者と患者が一体となって取り組んでいくことが重要です。

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer